Stay updated with breaking news from David Nikodem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HeparDx is an emerging NASH/MASH and liver fibrosis blood test designed to diagnose patients earlier and monitor disease progression The data presentations add...
Daix , Long Island City , August 31, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with...
Houston-based company will pay $65 million in cash and stock for AltheaDx, which makes a pharmacogenomics tests to guide clinicians on drug therapies for depression and anxiety.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ: CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Bioscienc...